Prior therapy was balanced between arms and included (neo)adjuvant chemotherapy in 55% of patients, endocrine therapy for aBC in 46%, PI3K/mTOR inhibitor in 24% (predominantly everolimus) and CDK4/6 inhibitor in 26%. This evidence concerns the gene MTOR and aneurysmal bone cyst.